Mount Yale Investment Advisors LLC Acquires 11,632 Shares of Kenvue Inc. (NYSE:KVUE)

Mount Yale Investment Advisors LLC increased its holdings in Kenvue Inc. (NYSE:KVUE) by 50.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 34,599 shares of the company’s stock after purchasing an additional 11,632 shares during the period. Mount Yale Investment Advisors LLC’s holdings in Kenvue were worth $739,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in KVUE. Public Sector Pension Investment Board increased its holdings in shares of Kenvue by 92.9% in the second quarter. Public Sector Pension Investment Board now owns 73,637 shares of the company’s stock worth $1,339,000 after purchasing an additional 35,461 shares during the last quarter. AQR Capital Management LLC grew its holdings in Kenvue by 427.0% during the 2nd quarter. AQR Capital Management LLC now owns 1,178,988 shares of the company’s stock valued at $21,434,000 after buying an additional 955,283 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Kenvue by 18.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,027,727 shares of the company’s stock worth $36,864,000 after acquiring an additional 314,086 shares during the last quarter. Mackenzie Financial Corp raised its holdings in shares of Kenvue by 0.8% during the 2nd quarter. Mackenzie Financial Corp now owns 385,294 shares of the company’s stock worth $7,005,000 after acquiring an additional 2,907 shares in the last quarter. Finally, Creative Planning boosted its position in shares of Kenvue by 15.4% during the 2nd quarter. Creative Planning now owns 379,045 shares of the company’s stock valued at $6,891,000 after acquiring an additional 50,562 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on KVUE shares. Citigroup decreased their price target on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. Piper Sandler upgraded shares of Kenvue from a “neutral” rating to an “overweight” rating and upped their target price for the company from $21.00 to $26.00 in a research report on Monday, January 6th. Barclays dropped their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday, January 17th. JPMorgan Chase & Co. raised their price objective on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Finally, UBS Group cut their target price on Kenvue from $24.00 to $23.00 and set a “neutral” rating on the stock in a research report on Thursday, January 16th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $23.08.

Kenvue Stock Performance

Shares of NYSE:KVUE opened at $21.36 on Wednesday. The firm’s 50 day simple moving average is $22.05 and its 200-day simple moving average is $21.85. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The firm has a market cap of $40.95 billion, a PE ratio of 38.84, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.27 by $0.01. The company had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. Kenvue’s quarterly revenue was down .4% on a year-over-year basis. During the same period last year, the business posted $0.31 EPS. As a group, equities analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a $0.205 dividend. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.84%. Kenvue’s payout ratio is currently 149.09%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.